Clinical trials
Parkinson Disease trials in Canada with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
46 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2012 | 1 |
| 2013 | 3 |
| 2015 | 4 |
| 2016 | 8 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 46 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Life Financial Movement Disorders Research and Rehabilitation Centre | 7 |
| University of Calgary | 5 |
| University of Toronto | 5 |
| University Health Network, Toronto | 4 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 3 |
| University of British Columbia | 3 |
| Western University, Canada | 3 |
| Wilfrid Laurier University | 2 |
| Alexandra Marine and General Hospital | 1 |
| Czech Technical University in Prague | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Parkinson Disease | 46 |
| Alzheimer Disease | 2 |
| Cognitive Dysfunction | 2 |
| Dementia | 2 |
| Gait Disorders, Neurologic | 2 |
| Parkinsonian Disorders | 2 |
| Speech Disorders | 2 |
| Anxiety Disorders | 1 |
| Dementia, Vascular | 1 |
| Disease | 1 |
Trials
Showing 1 to 25 of 46. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.